ANIK - Anika Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue103,37992,999105,595
Cost of Revenue24,02721,05320,930
Gross Profit79,35271,94684,665
Operating Expenses
Research Development10,7328,9878,144
Selling General and Administrative18,01314,82515,074
Non Recurring---
Total Operating Expenses---
Operating Income or Loss50,60748,13461,447
Income from Continuing Operations
Total Other Income/Expenses Net26312058
Earnings Before Interest and Taxes50,87048,25461,505
Interest Expense---
Income Before Tax50,87048,25461,505
Income Tax Expense18,32317,49623,186
Minority Interest---
Net Income From Continuing Ops32,54730,75838,319
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income32,54730,75838,319
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares32,54730,75838,319